These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care. Simeone E; Grimaldi AM; Festino L; Vanella V; Palla M; Ascierto PA BioDrugs; 2017 Feb; 31(1):51-61. PubMed ID: 28058658 [TBL] [Abstract][Full Text] [Related]
7. Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway. Grimaldi AM; Simeone E; Festino L; Vanella V; Palla M; Ascierto PA Discov Med; 2015 Jun; 19(107):455-61. PubMed ID: 26175403 [TBL] [Abstract][Full Text] [Related]
8. BRAF inhibitors in cancer therapy. Hertzman Johansson C; Egyhazi Brage S Pharmacol Ther; 2014 May; 142(2):176-82. PubMed ID: 24325952 [TBL] [Abstract][Full Text] [Related]
9. BRAF/MEK inhibitors for BRAF V600E-mutant cancers in non-approved setting: a case series. Butt SU; Mejias A; Morelli C; Torga G; Happe M; Patrikidou A; Arkenau HT Cancer Chemother Pharmacol; 2021 Mar; 87(3):437-441. PubMed ID: 33537843 [TBL] [Abstract][Full Text] [Related]
10. Concurrent MEK targeted therapy prevents MAPK pathway reactivation during BRAFV600E targeted inhibition in a novel syngeneic murine glioma model. Grossauer S; Koeck K; Murphy NE; Meyers ID; Daynac M; Truffaux N; Truong AY; Nicolaides TP; McMahon M; Berger MS; Phillips JJ; James CD; Petritsch CK Oncotarget; 2016 Nov; 7(46):75839-75853. PubMed ID: 27713119 [TBL] [Abstract][Full Text] [Related]
11. BRAF kinase inhibitors for treatment of melanoma: developments from early-stage animal studies to Phase II clinical trials. Fujimura T; Hidaka T; Kambayashi Y; Aiba S Expert Opin Investig Drugs; 2019 Feb; 28(2):143-148. PubMed ID: 30556435 [TBL] [Abstract][Full Text] [Related]
12. MEK inhibitors in oncology: a patent review (2015-Present). Mahapatra DK; Asati V; Bharti SK Expert Opin Ther Pat; 2017 Aug; 27(8):887-906. PubMed ID: 28594589 [TBL] [Abstract][Full Text] [Related]
13. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma. Menzies AM; Long GV Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796 [TBL] [Abstract][Full Text] [Related]
14. BRAF inhibitors in BRAF-V600 mutated primary neuroepithelial brain tumors. Preusser M; Bienkowski M; Birner P Expert Opin Investig Drugs; 2016; 25(1):7-14. PubMed ID: 26536389 [TBL] [Abstract][Full Text] [Related]
15. EGFR blockade prevents glioma escape from BRAFV600E targeted therapy. Yao TW; Zhang J; Prados M; Weiss WA; James CD; Nicolaides T Oncotarget; 2015 Sep; 6(26):21993-2005. PubMed ID: 26023796 [TBL] [Abstract][Full Text] [Related]
16. Therapeutic efficacy of combined BRAF and MEK inhibition in metastatic melanoma: a comprehensive network meta-analysis of randomized controlled trials. Mai R; Zhou S; Zhong W; Rong S; Cong Z; Li Y; Xie Q; Chen H; Li X; Liu S; Cheng Y; Huang Y; Zhou Y; Zhang G Oncotarget; 2015 Sep; 6(29):28502-12. PubMed ID: 26143635 [TBL] [Abstract][Full Text] [Related]
17. Targeted Therapy for Melanoma. Wong DJ; Ribas A Cancer Treat Res; 2016; 167():251-62. PubMed ID: 26601866 [TBL] [Abstract][Full Text] [Related]
18. [Melanoma]. Uhara H Gan To Kagaku Ryoho; 2016 Apr; 43(4):404-7. PubMed ID: 27220785 [TBL] [Abstract][Full Text] [Related]
19. Acquired resistance to BRAF inhibition can confer cross-resistance to combined BRAF/MEK inhibition. Gowrishankar K; Snoyman S; Pupo GM; Becker TM; Kefford RF; Rizos H J Invest Dermatol; 2012 Jul; 132(7):1850-9. PubMed ID: 22437314 [TBL] [Abstract][Full Text] [Related]